TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26115797

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (7.5 mg/kg every 3 weeks, continued with up to 12 further cycles)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Standard chemotherapy (six 3-weekly cycles of intravenous carboplatin [AUC 5 or 6] and paclitaxel 175 mg/m2)
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (in poor prognosis subgroup)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Standard chemotherapy (in poor prognosis subgroup)
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (in non-high-risk patients)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Standard chemotherapy (in non-high-risk patients)
Number of subjects: 1528
Study: 23631112

Group type: EXPERIMENTAL
Intervention: Experimental tooth clenching at 10%, 20%, or 40% of maximal voluntary clenching force (MVCF) for 60 minutes with follow-ups at 24 and 48 hours.
Number of subjects: 76

Group type: COMPARATOR
Intervention: 20-minute repetitive experimental tooth clenching task at 50% of MVCF.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Experimental tooth clenching in patients with M‐TMD.
Number of subjects: 76
Study: 21135703

Group type: EXPERIMENTAL
Intervention: Alfentanyl (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl (n=50)
Number of subjects: 100
Study: 19101777

Group type: EXPERIMENTAL
Intervention: Dual users of VA and non-VA care
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Dual users of physical health services
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Dual users of emotional health services
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Factors associated with dual use
Number of subjects: 550
Study: 17848651

Group type: EXPERIMENTAL
Intervention: Carvedilol (low-dose: 0.2 mg/kg per dose if weight <62.5 kg or 12.5 mg per dose if weight >=62.5 kg; high-dose: 0.4 mg/kg per dose if weight <62.5 kg or 25 mg per dose if weight >=62.5 kg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Combined carvedilol group
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 161
Study: 15545293

Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 41000

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 41000

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (aged 65-75)
Number of subjects: 41000
Study: 11281561

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 404

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 404

Group type: COMPARATOR
Intervention: Baseline cirrhosis
Number of subjects: 404

Group type: COMPARATOR
Intervention: Age comparison
Number of subjects: 404
Study: 9441075

Group type: EXPERIMENTAL
Intervention: BCG immunization
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (non-immunized infants)
Number of subjects: 33
Study: 8470032

Group type: COMPARATOR
Intervention: FGR (BACOP, COPP, CHOP, CNOP)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: CAVPE
Number of subjects: 449

Group type: COMPARATOR
Intervention: FGR
Number of subjects: 449
Study: 3546612

Group type: EXPERIMENTAL
Intervention: Lumpectomy/radiation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Combination chemotherapy (Adriamycin plus Cytoxan or methotrexate plus 5-FU)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Baseline distress factors (fatigue/depression, lack of social support)
Number of subjects: 75
Study: 30060770

Group type: EXPERIMENTAL
Intervention: Enhanced disinfection strategies for terminal room disinfection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard practice disinfection
Number of subjects: 0
Study: 27430587

Group type: EXPERIMENTAL
Intervention: Intensive low-calorie meal replacement diet (ILCD, 960 kcal/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Balanced deficit diet (BDD, 500 kcal/day below estimated energy needs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (ILCD and BDD)
Number of subjects: 28
Study: 24456998

Group type: EXPERIMENTAL
Intervention: Multi-modal intervention (specific clinical targets, education, diet, and resistance training exercise)
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1718
Study: 22327088

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (268 mg·d⁻¹)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (glucose: 30 mg·d⁻¹)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 12
Study: 20121752

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuation of original immunosuppression
Number of subjects: 44
Study: 18030229

Group type: EXPERIMENTAL
Intervention: Esomeprazole 0.25 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Esomeprazole 1 mg/kg
Number of subjects: 50
Study: 16102683

Group type: EXPERIMENTAL
Intervention: Propofol TCI (Diprifusor pharmacokinetic model) starting at 4 microg/mL, adjusted by 0.4 microg/mL step size
Number of subjects: 60
Study: 12120768

Group type: EXPERIMENTAL
Intervention: Medium-filled flowable restorative material (CuRay-Match)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unfilled sealant (Delton)
Number of subjects: 32
Study: 10231510

Group type: EXPERIMENTAL
Intervention: 100 microg recombinant human platelet‐derived growth factor‐BB daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 300 microg recombinant human platelet‐derived growth factor‐BB daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 100 microg recombinant human platelet‐derived growth factor‐BB bid
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 7503191

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (singleton pregnancies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (twin pregnancies)
Number of subjects: 0
Study: 1348481

Group type: EXPERIMENTAL
Intervention: celiprolol 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: propranolol 40 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: celiprolol 400 mg plus propranolol 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo plus propranolol 40 mg
Number of subjects: 10
Study: 2860740

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) plus Persantine (75 mg) four times daily
Number of subjects: 890

Group type: COMPARATOR
Intervention: Aspirin (325 mg) plus placebo
Number of subjects: 890
Study: 28567529

Group type: EXPERIMENTAL
Intervention: Face-bow registration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mean settings with Bonwill triangle and Balkwill angle
Number of subjects: 32
Study: 27717210

Group type: EXPERIMENTAL
Intervention: CAF + CMX (xenogeneic collagen matrix)
Number of subjects: 45

Group type: COMPARATOR
Intervention: CAF (coronally advanced flap)
Number of subjects: 45
Study: 26336072

Group type: EXPERIMENTAL
Intervention: General information about heart disease and written advice to attend their GP for CVD risk assessment
Number of subjects: 97

Group type: COMPARATOR
Intervention: General information about heart disease only
Number of subjects: 97
Study: 23922470

Group type: EXPERIMENTAL
Intervention: Single-balloon colonoscopy (SBC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Double-balloon colonoscopy (DBC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (Conventional colonoscopy)
Number of subjects: 21
Study: 21670714

Group type: EXPERIMENTAL
Intervention: Mean ICP wave amplitude (MWA) guided intensive care management
Number of subjects: 97

Group type: COMPARATOR
Intervention: Mean ICP management (less than 20 mm Hg)
Number of subjects: 97
Study: 18797149

Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17369904

Group type: EXPERIMENTAL
Intervention: Poetam (affinity‐purified antibodies to recombinant human erythropoietin) combined with iron preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with Poetam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorbifer (iron preparation)
Number of subjects: 0
Study: 14669170

Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg twice daily or 150 microg 3 times a day)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 11271081

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (100 mg bolus, 10 mg/h for 7 days and subsequent tapering)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy
Number of subjects: 20
Study: 8830301

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg, p.o.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2368376

Group type: EXPERIMENTAL
Intervention: Low-to-moderate-intensity walking program (mean 69% of maximal heart rate), 40-45 minutes, three times per week for two months.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise intervention).
Number of subjects: 16
Study: 110129

Group type: EXPERIMENTAL
Intervention: Essential amino acids plus arginine and histidine infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: General amino acid solution infusion
Number of subjects: 6
Study: 29788823

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 30866485

Group type: EXPERIMENTAL
Intervention: Skate skin collagen peptides (SCP) 2000 mg per day for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27869986

Group type: EXPERIMENTAL
Intervention: AD + PE (sertraline plus physical exercise)
Number of subjects: 121

Group type: COMPARATOR
Intervention: AD (sertraline)
Number of subjects: 121
Study: 26887210

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (n=48)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Routine acupuncture group (n=49)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Para-BL10 group (n=48)
Number of subjects: 145
Study: 24021323

Group type: EXPERIMENTAL
Intervention: Aqueous liquorice mouthwash (15%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ethanolic liquorice mouthwash (3.75%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate (0.156%)
Number of subjects: 60
Study: 22044549

Group type: EXPERIMENTAL
Intervention: Physical Coordination Training (PCT)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Training (CBTr)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Reference Group (REF)
Number of subjects: 294
Study: 19447358

Group type: EXPERIMENTAL
Intervention: GSH/MI treatment (6 guided self-help sessions and 2 sessions utilizing an MI approach)
Number of subjects: 39

Group type: COMPARATOR
Intervention: GSH treatment (6 sessions of traditional guided self-help and 2 traditional motivation-focused sessions)
Number of subjects: 39
Study: 16822117

Group type: EXPERIMENTAL
Intervention: Clinic-based cognitive-behavior therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clinic-plus-Internet cognitive-behavior therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 72
Study: 12918634

Group type: EXPERIMENTAL
Intervention: Keep on Talking program (experimental group)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Communication assessment (control group)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Active Communication Education program (preliminary outcomes, n = 14)
Number of subjects: 250
Study: 11775909

Group type: EXPERIMENTAL
Intervention: Estrogen group (19 cases)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone group (23 cases)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo group (10 cases)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (20 healthy premenopausal women)
Number of subjects: 52
Study: 9099388

Group type: EXPERIMENTAL
Intervention: Flumethasone (10 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dinoprost (25 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 45
Study: 8344093

Group type: COMPARATOR
Intervention: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 2 g acetaminophen dose
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 4 g acetaminophen dose
Number of subjects: 19

Group type: COMPARATOR
Intervention: Activated charcoal after 4 g acetaminophen dose
Number of subjects: 19
Study: 3325490

Group type: EXPERIMENTAL
Intervention: 27-h fast
Number of subjects: 9

Group type: COMPARATOR
Intervention: Preexercise meal
Number of subjects: 9
Study: 29243031

Group type: COMPARATOR
Intervention: High-dose cytarabine (HiDAC)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 240
Study: 27650788

Group type: EXPERIMENTAL
Intervention: Average weight version of patient information materials
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard patient information version on confidence intervals (control group)
Number of subjects: 64
Study: 24245978

Group type: EXPERIMENTAL
Intervention: 1,064 nm Q-Switched Nd:YAG laser plus chemical peeling with Jessner's solution (Group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1,064 nm Q-Switched Nd:YAG laser plus placebo chemical peeling (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 52
Study: 23734252

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) as determined by a portable device
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 96
Study: 19937457

Group type: EXPERIMENTAL
Intervention: Balneotherapy in mineral water
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 42
Study: 18320806

Group type: EXPERIMENTAL
Intervention: Surgery alone for thoracic esophageal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study: 15920347

Group type: EXPERIMENTAL
Intervention: High-dose induction interferon (10 MU daily for the first week) plus ribavirin (1,000 mg/day for 24 weeks) - HR group (n = 29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional combination therapy (3 MU interferon three times weekly plus ribavirin 1,000 mg/day for 24 weeks) - CR group (n = 30)
Number of subjects: 59
Study: 14629854

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Conventional standard therapy
Number of subjects: 1062
Study: 10376459

Group type: EXPERIMENTAL
Intervention: Water intubation technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 100
Study: 8669100

Group type: EXPERIMENTAL
Intervention: FK506 (0.2 mg/kg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 120
Study: 1839993

Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (200 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of fenoterol and ipratropium bromide (200 micrograms and 40 micrograms respectively)
Number of subjects: 20
Study: 6481115

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 32
Study: 31477046

Group type: EXPERIMENTAL
Intervention: Third trimester routine ultrasound
Number of subjects: 15
Study: 28771918

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) followed by Positive Psychology Intervention (PPI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention (PPI) followed by Cognitive Behavioural Therapy (CBT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both CBT and PPI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 40
Study: 26103559

Group type: EXPERIMENTAL
Intervention: Implants with acid-etched surface combined with local application of melatonin gel at the osteotomy site
Number of subjects: 14

Group type: COMPARATOR
Intervention: Implants with acid-etched surface
Number of subjects: 14
Study: 25050592

Group type: EXPERIMENTAL
Intervention: Oxycodone once daily (OOD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oxycodone twice daily (OTD)
Number of subjects: 68
Study: 23121995

Group type: EXPERIMENTAL
Intervention: Strengthened routine information system (RIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of investment to strengthen RIS
Number of subjects: 0
Study: 19244043

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (CRT)
Number of subjects: 53
Study: 17312215

Group type: EXPERIMENTAL
Intervention: Automated reminders (pager and e-mail)
Number of subjects: 2459

Group type: COMPARATOR
Intervention: No reminders (Control group)
Number of subjects: 2459

Group type: EXPERIMENTAL
Intervention: All staff receiving reminders after 2 months
Number of subjects: 2459

Group type: EXPERIMENTAL
Intervention: Projected compliance rate over 12 months
Number of subjects: 2459
Study: 15343550

Group type: EXPERIMENTAL
Intervention: Information only
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Coping only
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Coping plus information
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study: 11640994

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 423
Study: 9840607

Group type: EXPERIMENTAL
Intervention: Oxfendazole (OFZ) 30 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 20
Study: 7977115

Group type: EXPERIMENTAL
Intervention: Balloon occlusion in group 1 (mild to moderate stenosis)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Balloon occlusion in group 2 (severe stenosis)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no ischemia)
Number of subjects: 50
Study: 2610332

Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with egg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with wheat
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with milk
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with soya
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food additives (DBPCC) with tyramine and acetylsalicylic acid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food additive tartrazine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food additive sodium benzoate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food additive sodium glutamate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food additive sodium metabisulfite
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food additive acetylsalicylic acid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Food additive tyramine
Number of subjects: 25
Study: 30920439

Group type: EXPERIMENTAL
Intervention: Motivational counseling program (12 weeks)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lifestyle modification brochure (comparison group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 115
Study: 29180592

Group type: EXPERIMENTAL
Intervention: Preferred intensity exercise programme (12 sessions of circuit training over 6 weeks, supervised by a qualified exercise therapist)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 86
Study: 26189234

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (chewed for 1 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated group (no intervention)
Number of subjects: 10
Study: 23274503

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study: 21678032

Group type: EXPERIMENTAL
Intervention: Multi-component intervention to increase CRC screening
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Multi-component intervention with provider letter
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Adjustment for self-report bias and missing data
Number of subjects: 548
Study: 20002929

Group type: EXPERIMENTAL
Intervention: Bleaching with 20% carbamide peroxide (Opalescence PF 20%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nonbleaching group (stored in distilled water)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Staining solutions (coffee and tea)
Number of subjects: 42
Study: 16674606

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 1,200 mg/day
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 1,800 mg/day
Number of subjects: 347

Group type: COMPARATOR
Intervention: Oxcarbazepine 600 mg/day
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 15203576

Group type: EXPERIMENTAL
Intervention: Insulin lispro (IL) administered before meals
Number of subjects: 9

Group type: COMPARATOR
Intervention: Insulin lispro (IL) administered after meals
Number of subjects: 9
Study: 11419234

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no CBT training)
Number of subjects: 29
Study: 9260008

Group type: EXPERIMENTAL
Intervention: Needle orifice cephalad (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Needle orifice caudad (group II)
Number of subjects: 40
Study: 8291367

Group type: EXPERIMENTAL
Intervention: Vancomycin (vanco+)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (vanco-)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59